Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals (NQ: AGIO )

47.21 +0.60 (+1.29%)
Streaming Delayed Price Updated: 11:19 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 37,290
Open 46.86
Bid (Size) 47.13 (4)
Ask (Size) 47.31 (4)
Prev. Close 46.61
Today's Range 46.55 - 47.35
52wk Range 19.80 - 49.05
Shares Outstanding 58,951,469
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings For Agios Pharmaceuticals
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Performance

YTD
+106.79%
+106.79%
1 Month
+4.40%
+4.40%
3 Month
+56.27%
+56.27%
6 Month
+118.36%
+118.36%
1 Year
+79.30%
+79.30%

More News

Read More
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Via Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Via InvestorPlace
Why Is Agios Pharmaceuticals Stock Trading Higher On Monday?
Via Benzinga
Earnings Scheduled For February 15, 2024
Via Benzinga
Earnings Preview: Agios Pharmaceuticals
Via Benzinga
RBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Nvidia Again Boosts Nasdaq To Record Highs
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
Via Benzinga
Exposures Product Safety
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Attention Biotech Investors - Stocks To Watch
Via Benzinga
AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Via InvestorPlace
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Via Investor's Business Daily
7 Biotech Stocks Fighting America’s Deadliest Diseases
Via InvestorPlace
Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today?
Via Benzinga
Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia Drug
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.